| heart failure | versus placebo or no treatment No demonstrated result for efficacy perindopril inferior to placebo in terms of NYHA class improvement in Lechat, 1993 perindopril inferior to placebo in terms of Hospitalisation in PEP CHF, 2006 | 2 trials | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| Lechat, 1993 | perindopril vs placebo | | NYHA class improvement 2.03 [1.24; 3.32] | all cause death or hospitalisation 0.00 [0.00; NaN] | | PEP CHF, 2006 | perindopril vs placebo | | Hospitalisation 0.64 [0.43; 0.97] | Death 0.90 [0.47; 1.71] Long term death (1 year) 0.90 [0.47; 1.71] all cause death or hospitalisation 0.69 [0.47; 1.02] |
| Trial | Treatments | Patients | Method |
|---|
| Lechat, 1993 | perindopril, 2 mg once daily (n=61) vs. placebo (n=64) | patients with grade II or III New York Heart Association chronic congestive heart failure on baseline diuretic therapy | double blind Sample size: 61/64 Primary endpoint: FU duration: 3-month | | PEP CHF, 2006 | perindopril, 4 mg/day (n=424) vs. placebo (n=426) | patients aged >=70 years with a diagnosis of heart failure, treated with diuretics and an echocardiogram
suggesting diastolic dysfunction and excluding substantial LV systolic dysfunction or valve disease | double blind Parallel groups Sample size: 424/426 Primary endpoint: all-cause mortality and unplanned heart failure related hospitalization FU duration: 26.2 months (range 12-54.2m) |
|
| heart failure with preserved LVEF | versus placebo or no treatment No demonstrated result for efficacy perindopril inferior to placebo in terms of Hospitalisation in PEP CHF, 2006 | 1 trial | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| PEP CHF, 2006 | perindopril vs placebo | | Hospitalisation 0.64 [0.43; 0.97] | Death 0.90 [0.47; 1.71] Long term death (1 year) 0.90 [0.47; 1.71] all cause death or hospitalisation 0.69 [0.47; 1.02] |
| Trial | Treatments | Patients | Method |
|---|
| PEP CHF, 2006 | perindopril, 4 mg/day (n=424) vs. placebo (n=426) | patients aged >=70 years with a diagnosis of heart failure, treated with diuretics and an echocardiogram
suggesting diastolic dysfunction and excluding substantial LV systolic dysfunction or valve disease | double blind Parallel groups Sample size: 424/426 Primary endpoint: all-cause mortality and unplanned heart failure related hospitalization FU duration: 26.2 months (range 12-54.2m) |
|
| patients at high risk for cardiovascular events | versus placebo or control No demonstrated result for efficacy perindopril inferior to placebo in terms of Toux in EUROPA, 2003 perindopril inferior to placebo in terms of hypotension in EUROPA, 2003 perindopril inferior to placebo in terms of Arrêt pour effet secondaire in EUROPA, 2003 | 1 trial | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| EUROPA, 2003 | perindopril vs placebo | Crit principaux 0.81 [0.72; 0.91] EUROPA endpoint 0.81 [0.72; 0.91] Ev. coronariens 0.77 [0.66; 0.88] Infarctus non mortel 0.78 [0.67; 0.90] Ev. cardiovasculaires 0.81 [0.72; 0.91] | Toux 5.06 [3.47; 7.38] hypotension 3.53 [2.06; 6.04] Arrêt pour effet secondaire 1.10 [1.03; 1.17] | Insuffisance rénale 1.25 [0.65; 2.41] Mortalité totale 0.89 [0.78; 1.02] Décès cardiovasculaires 0.86 [0.72; 1.03] revascularisation 0.96 [0.86; 1.07] AVC mortels et non mortels 0.96 [0.73; 1.26] |
| Trial | Treatments | Patients | Method |
|---|
| EUROPA, 2003 | perindopril 8 mg once daily (n=6110) vs. placebo (n=6108) | low-risk patients with stable coronary heart disease and no apparent heart failure | double blind Parallel groups Sample size: 6110/6108 Primary endpoint: cardiovascular death, myocardial infarction, or cardiac arrest FU duration: 4.2y |
|
